Sylvia Lise Ranjeva, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cross Protection | 1 | 2019 | 25 | 0.650 |
Why?
|
Alphapapillomavirus | 1 | 2017 | 219 | 0.480 |
Why?
|
Papillomaviridae | 1 | 2019 | 1140 | 0.430 |
Why?
|
Immunologic Memory | 1 | 2019 | 1377 | 0.400 |
Why?
|
Papillomavirus Infections | 2 | 2019 | 1640 | 0.320 |
Why?
|
Influenza, Human | 1 | 2019 | 1541 | 0.290 |
Why?
|
Antibodies, Viral | 1 | 2019 | 3214 | 0.290 |
Why?
|
Lung | 1 | 2024 | 10101 | 0.250 |
Why?
|
Postoperative Complications | 2 | 2024 | 15833 | 0.230 |
Why?
|
Models, Biological | 1 | 2019 | 9497 | 0.210 |
Why?
|
Neuroma | 1 | 2024 | 138 | 0.200 |
Why?
|
Biota | 1 | 2019 | 23 | 0.170 |
Why?
|
Myocardial Infarction | 1 | 2020 | 11519 | 0.160 |
Why?
|
Hong Kong | 1 | 2019 | 170 | 0.160 |
Why?
|
Hemagglutinins | 1 | 2019 | 111 | 0.160 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2019 | 85 | 0.160 |
Why?
|
Cell Membrane Structures | 1 | 2015 | 24 | 0.130 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2019 | 452 | 0.120 |
Why?
|
Morbidity | 1 | 2020 | 1755 | 0.120 |
Why?
|
Neisseria meningitidis | 1 | 2015 | 111 | 0.120 |
Why?
|
Antigens, Viral | 1 | 2019 | 995 | 0.120 |
Why?
|
Hydrocephalus | 2 | 2012 | 768 | 0.120 |
Why?
|
Models, Statistical | 2 | 2019 | 5107 | 0.110 |
Why?
|
Tropical Climate | 1 | 2012 | 35 | 0.100 |
Why?
|
Rain | 1 | 2012 | 60 | 0.100 |
Why?
|
Respiratory Mucosa | 1 | 2015 | 439 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 2019 | 781 | 0.090 |
Why?
|
Seasons | 2 | 2012 | 1524 | 0.080 |
Why?
|
Gram-Negative Bacteria | 1 | 2011 | 275 | 0.080 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2011 | 238 | 0.080 |
Why?
|
Adaptation, Physiological | 1 | 2015 | 1312 | 0.080 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2011 | 1049 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2020 | 5349 | 0.070 |
Why?
|
Risk Factors | 3 | 2024 | 74944 | 0.060 |
Why?
|
DNA, Bacterial | 1 | 2011 | 1478 | 0.060 |
Why?
|
Retrospective Studies | 3 | 2024 | 81760 | 0.060 |
Why?
|
Recurrence | 1 | 2017 | 8509 | 0.060 |
Why?
|
Adult | 4 | 2024 | 223646 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2019 | 14783 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18415 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10397 | 0.050 |
Why?
|
Humans | 9 | 2024 | 768171 | 0.050 |
Why?
|
Incidence | 1 | 2019 | 21538 | 0.040 |
Why?
|
Prevalence | 1 | 2017 | 15869 | 0.040 |
Why?
|
Adolescent | 2 | 2019 | 89169 | 0.040 |
Why?
|
Prospective Studies | 1 | 2024 | 54924 | 0.040 |
Why?
|
Risk Assessment | 1 | 2020 | 24318 | 0.040 |
Why?
|
Child, Preschool | 2 | 2019 | 42669 | 0.040 |
Why?
|
Aged | 3 | 2024 | 171502 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39354 | 0.040 |
Why?
|
Time Factors | 1 | 2019 | 40220 | 0.040 |
Why?
|
Uganda | 2 | 2012 | 1361 | 0.030 |
Why?
|
Middle Aged | 3 | 2024 | 223487 | 0.030 |
Why?
|
Male | 5 | 2024 | 364731 | 0.030 |
Why?
|
Peptidoglycan | 1 | 2015 | 246 | 0.030 |
Why?
|
Child | 2 | 2019 | 80917 | 0.030 |
Why?
|
Africa, Eastern | 1 | 2012 | 76 | 0.030 |
Why?
|
United States | 1 | 2020 | 73039 | 0.030 |
Why?
|
Young Adult | 1 | 2019 | 60066 | 0.020 |
Why?
|
Nasopharynx | 1 | 2015 | 420 | 0.020 |
Why?
|
Proteobacteria | 1 | 2011 | 47 | 0.020 |
Why?
|
Biological Evolution | 1 | 2015 | 1076 | 0.020 |
Why?
|
Cohort Studies | 2 | 2024 | 41753 | 0.020 |
Why?
|
Female | 3 | 2024 | 397187 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2015 | 3445 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6082 | 0.010 |
Why?
|
Infant | 2 | 2012 | 36535 | 0.010 |
Why?
|
Algorithms | 1 | 2012 | 14164 | 0.010 |
Why?
|